Disease · EFO_0005762

neuropathic pain

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. neuropathic pain. Diseases, record EFO_0005762. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0005762

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: neuropathic pain; Open Targets
Open Targets ID: EFO_0005762; Open Targets
NCI Thesaurus: C96210; NCI Thesaurus
Highest stage of its drugs: Approval, for 5 of its 154 drugs, from DailyMed and TTD; Open Targets

Drugs154

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
PREGABALIN	CHEMBL1059	Small molecule	Approval	DailyMed	100	51	51	Drugs and targets
CAPSAICIN	CHEMBL294199	Small molecule	Approval	DailyMed and TTD	16	13	13	Drugs and targets
CLONIDINE	CHEMBL134	Small molecule	Approval	DailyMed	4	3	3	Drugs and targets
TAPENTADOL HYDROCHLORIDE	CHEMBL1201777	Small molecule	Approval	DailyMed	5	1	1	Drugs and targets
DULOXETINE HYDROCHLORIDE	CHEMBL1200328	Small molecule	Approval	DailyMed	5	0	0	Drugs and targets
LIDOCAINE	CHEMBL79	Small molecule	Phase 3	ClinicalTrials.gov	21	21	21	Drugs and targets
GABAPENTIN	CHEMBL940	Small molecule	Phase 3	ClinicalTrials.gov	12	11	11	Drugs and targets
KETAMINE	CHEMBL742	Small molecule	Phase 3	ClinicalTrials.gov and TTD	9	8	8	Drugs and targets
DRONABINOL	CHEMBL465	Small molecule	Phase 3	ClinicalTrials.gov	6	6	5	Drugs and targets
AMITRIPTYLINE	CHEMBL629	Small molecule	Phase 3	ClinicalTrials.gov and TTD	6	5	5	Drugs and targets

1 to 10 of 154

See all 154 drugs

Targets205

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
SCN4A	Sodium channel alpha subunit	12	Sodium channel alpha subunit blocker; Sodium channel protein type IV alpha subunit blocker	Phase 3	https://conductscience.org/library/genes/6329	Drugs and targets
SCN9A	Sodium channel alpha subunit	11	Sodium channel alpha subunit blocker; Sodium channel protein type IX alpha subunit blocker	Phase 3	https://conductscience.org/library/genes/6335	Drugs and targets
SLC6A4	Monoamine transporter	11	Monoamine transporter inhibitor; Serotonin transporter inhibitor; Sodium-dependent serotonin transporter releasing agent	Approval	https://conductscience.org/library/genes/6532	Drugs and targets
GRIN1	Glutamate NMDA receptor; GRIN1/GRIN2B	10	Glutamate NMDA receptor; GRIN1/GRIN2B antagonist; Glutamate [NMDA] receptor antagonist; Glutamate [NMDA] receptor blocker; Glutamate [NMDA] receptor negative allosteric modulator	Phase 3	https://conductscience.org/library/genes/2902	Drugs and targets
GRIN2B	Glutamate NMDA receptor; GRIN1/GRIN2B	10	Glutamate NMDA receptor; GRIN1/GRIN2B antagonist; Glutamate [NMDA] receptor antagonist; Glutamate [NMDA] receptor blocker; Glutamate [NMDA] receptor negative allosteric modulator	Phase 3	https://conductscience.org/library/genes/2904	Drugs and targets
SCN10A	Sodium channel alpha subunit	10	Sodium channel alpha subunit blocker; Sodium channel protein type X alpha subunit blocker	Phase 3	https://conductscience.org/library/genes/6336	Drugs and targets
SCN5A	Sodium channel alpha subunit	10	Sodium channel alpha subunit blocker; Sodium channel protein type V alpha subunit blocker	Phase 3	https://conductscience.org/library/genes/6331	Drugs and targets
SLC6A2	Monoamine transporter	10	Monoamine transporter inhibitor; Norepinephrine transporter inhibitor; Sodium-dependent noradrenaline transporter releasing agent	Approval	https://conductscience.org/library/genes/6530	Drugs and targets
GRIN2A	Glutamate [NMDA] receptor	9	Glutamate [NMDA] receptor antagonist; Glutamate [NMDA] receptor blocker; Glutamate [NMDA] receptor negative allosteric modulator; Glutamate [NMDA] receptor subunit epsilon 1 antagonist	Phase 3	https://conductscience.org/library/genes/2903	Drugs and targets
OPRM1	Mu-type opioid receptor	9	Mu opioid receptor agonist; Opioid receptors; mu/kappa/delta agonist	Approval	https://conductscience.org/library/genes/4988	Drugs and targets

1 to 10 of 205

See all 205 targets

Trials225

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 10 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00843284	Symptomatic Treatment Of Patients With Neuropathic Pain With LYRICA		691	2009-04-16	Neuropathic Pain	PREGABALIN	Its record names the disease	ClinicalTrials.gov
NCT01701362	Placebo-controlled Safety and Efficacy Study of Pregabalin in Subjects With Post-traumatic Peripheral Neuropathic Pain	Phase 3	542	2017-06-07	Neuropathic Pain	PREGABALIN	Its record names the disease	ClinicalTrials.gov
NCT01496365	Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy	Phase 2	452	2021-01-05	Diabetic Peripheral Neuropathy	MIROGABALIN BESYLATE, PREGABALIN	Its record names the disease	ClinicalTrials.gov
NCT00235443	A Follow-On Trial to Assess the Long Term Safety and Efficacy of SPM 927 in Painful Distal Diabetic Neuropathy	Phase 2/3	451	2009-10-05	Diabetic Neuropathy	LACOSAMIDE	Its record names the disease	ClinicalTrials.gov
NCT00643760	A Study In Patients With Neuropathic Pain From Diabetic Peripheral Neuropathy (DPN)	Phase 2	421	2011-05-11	Neuropathy, Diabetic	GABAPENTIN ENACARBIL, PREGABALIN	Its record names the disease	ClinicalTrials.gov
NCT00713323	A Study to Compare the Safety and Tolerability of Sativex® in Patients With Neuropathic Pain.	Phase 3	380	2012-09-14	Pain, Peripheral Neuropathy	NABIXIMOLS	Its record names the disease	ClinicalTrials.gov
NCT01049217	Pregabalin Versus Placebo In The Treatment Of Neuropathic Pain Associated With HIV Neuropathy	Phase 3	377	2013-07-17	Neuropathy	PREGABALIN	Its record names the disease	ClinicalTrials.gov
NCT00619476	A Study In Patients With Neuropathic Pain From Post-Herpetic Neuralgia (PHN)	Phase 2	376	2011-05-20	Neuralgia, Postherpetic	GABAPENTIN ENACARBIL	Its record names the disease	ClinicalTrials.gov
NCT01533428	A Study to Evaluate Efficacy and Safety of a Single Application of Capsaicin 8%Transdermal Delivery System Compared to Placebo in Reducing Pain Intensity in Subjects With Painful Diabetic Peripheral Neuropathy (PDPN)	Phase 3	369	2015-03-13	Diabetic Peripheral Neuropathy, Pain	CAPSAICIN	Its record names the disease	ClinicalTrials.gov
NCT00232141	Study of Pregabalin Versus Placebo in the Treatment of Nerve Pain Associated With HIV Neuropathy	Phase 3	302	2009-08-11	HIV Infections, Peripheral Neuropathy	PREGABALIN	Its record names the disease	ClinicalTrials.gov

1 to 10 of 225

See all 225 trials

Comparisons in its trials65

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Pregabalin vs Placebo: serious adverse events	2 of 274	7 of 265	539	NCT01701362	Trial comparisons
Pregabalin vs Placebo: serious adverse events	7 of 183	7 of 192	375	NCT01049217	Trial comparisons
Capsaicin 8% vs Placebo: serious adverse events	2 of 186	7 of 183	369	NCT01533428	Trial comparisons
Pregabalin vs Placebo: Number of Participants With Abnormal Laboratory Test Findings	165 of 180	170 of 183	363	NCT01049217	Trial comparisons
NYX-2925 vs Placebo: deaths from any cause	0 of 114	2 of 114	228	NCT04146896	Trial comparisons
NYX-2925 vs Placebo: serious adverse events	1 of 114	6 of 114	228	NCT04146896	Trial comparisons
NYX-2925 vs Placebo: Patient Global Impression of Change (PGI-C)	38 of 113	40 of 112	225	NCT04146896	Trial comparisons
NYX-2925 vs Placebo: Use of Rescue Medication	100 of 113	97 of 112	225	NCT04146896	Trial comparisons
NYX-2925 vs Placebo: Number of Subjects Achieving ≥50% Reduction	29 of 113	35 of 112	225	NCT04146896	Trial comparisons
NYX-2925 vs Placebo: Number of Subjects Achieving ≥30% Pain Reduction	51 of 113	52 of 112	225	NCT04146896	Trial comparisons

1 to 10 of 65

See all 65 comparisons in its trials

Papers from its trials140

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
42421175	RESULT	1	PubMed
38468350	RESULT	1	PubMed
38345071	RESULT	1	PubMed
38326195	RESULT	1	PubMed
38148266	RESULT	1	PubMed
38039630	RESULT	1	PubMed
37296029	RESULT	1	PubMed
36581838	RESULT	1	PubMed
36532184	RESULT	1	PubMed
36522043	RESULT	1	PubMed

1 to 10 of 140

See all 140 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/EFO_0005762

GET https://conductscience.org/api/diseases/v1/EFO_0005762/drugs?page=2

API reference For AI assistants